Skip to main content
Chongqing Pharscin Pharmaceutical Co., Ltd. logo

Chongqing Pharscin Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002907 ISIN · CNE100003308 LEI · 300300M2F5XMGFAYMA24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2025-04-24 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002907

About Chongqing Pharscin Pharmaceutical Co., Ltd.

https://www.pharscin.com

Chongqing Pharscin Pharmaceutical Co., Ltd. is an integrated enterprise specializing in the research, development, production, and commercialization of chemical drugs and modern traditional Chinese medicine. The company focuses on therapeutic areas such as digestive system health, cardiovascular and cerebrovascular diseases, and hepatobiliary conditions. Its portfolio includes a variety of proprietary formulations and generic medications, notably treatments for chronic liver disease and gastrointestinal disorders. Pharscin maintains advanced manufacturing facilities and a dedicated R&D infrastructure focused on enhancing drug efficacy and delivery systems. The organization emphasizes clinical value and technological innovation to provide comprehensive healthcare solutions across diverse medical sectors.

Recent filings

Filing Released Lang Actions
关于未来三年股东回报规划（2024年—2026年）的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Chongqing Huashen Pharmaceutical Co., Ltd. regarding its shareholder return plan for the next three years (2024-2026). It details the company's dividend policy, profit distribution principles, and mechanisms for shareholder returns. The text is a formal announcement outlining future plans rather than a report containing financial statements or results. The document length is 2575 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a full financial report, audit, or regulatory filing. It is not a dividend amount notice (DIV) because it does not specify dividend amounts or payment dates but rather a multi-year strategic plan for shareholder returns. Therefore, the best fitting category is a Regulatory Filing (RNS), as it is a formal regulatory announcement about company policy and plans that do not fit other specific categories.
2025-04-24 Chinese
独立董事候选人声明与承诺（李嘉明）
Board/Management Information Classification · 95% confidence The document is a detailed declaration and commitment statement by an independent director candidate for a company's board. It includes statements of qualifications, compliance with regulatory requirements, and commitments related to the role of an independent director. There is no financial data, no report of financial results, no voting results, no announcement of a meeting, no legal proceeding update, and no mention of capital or share transactions. The document is not a report but a formal declaration related to board/management information, specifically about a candidate for the board of directors. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 3433 characters, which is consistent with a detailed declaration rather than a brief announcement or a full report.
2025-04-24 Chinese
关于授权董事会制定2025年中期分红方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is a public announcement from Chongqing Huashen Pharmaceutical Co., Ltd. regarding the authorization of the board of directors to formulate the 2025 interim dividend plan. It discusses the conditions, timing, and authorization for the mid-year dividend distribution, and mentions that the proposal will be submitted to the 2024 annual shareholders' meeting for approval. The document is short (832 characters) and serves as an official notice about dividend planning and authorization rather than the actual dividend payment or detailed financial results. It does not contain financial statements or detailed financial data, nor is it a full report. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and related shareholder details.
2025-04-24 Chinese
独立董事候选人声明与承诺（杜守颖）
Board/Management Information Classification · 95% confidence The document is a detailed declaration and commitment statement from an independent director candidate of a company, outlining qualifications, compliance with regulatory requirements, and commitments related to the role. It does not contain financial data, audit results, or report content. It is not an announcement of voting results or a proxy solicitation but rather a formal statement related to board/management information, specifically about a director candidate's qualifications and commitments. Therefore, it fits best under Board/Management Information (MANG). The document length is 3435 characters, which is consistent with a detailed declaration rather than a full report or announcement.
2025-04-24 Chinese
关于调整公司组织架构的公告
Board/Management Information Classification · 95% confidence The document is an announcement from the board of directors of Chongqing Huashen Pharmaceutical Co., Ltd. regarding an adjustment to the company's organizational structure. It details the creation of new departments and their functions, and references a board meeting resolution. There is no financial data, no mention of annual or quarterly reports, no voting results, no legal proceedings, no capital changes, and no other report types. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management or organizational structure.
2025-04-24 Chinese
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2025 年第一季度报告" which translates to "2025 First Quarter Report". It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes on financial performance for the first quarter of 2025. The document explicitly states it is a quarterly report and mentions it is unaudited. The length of the document (12,518 characters) and the presence of comprehensive financial statements confirm it is a substantive financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-24 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.